^
Association details:
Biomarker:RET C620R
Cancer:Thyroid Gland Medullary Carcinoma
Drug:everolimus (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Excerpt:
The MEN2A MTC patient showed the best response upon everolimus therapy. Apart from the treatment effect, the RET c.1858T>C, p.Cys620Arg mutation has been associated with a less aggressive phenotype compared to other MEN2A-related mutations such as the c.2753T>C p.Met918Thr mutation or one of the classic mutations in exon 11 at codon 634...
DOI:
10.1155/2015/348124